Fátima Cardoso

64.9k total citations · 14 hit papers
403 papers, 25.4k citations indexed

About

Fátima Cardoso is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fátima Cardoso has authored 403 papers receiving a total of 25.4k indexed citations (citations by other indexed papers that have themselves been cited), including 259 papers in Oncology, 192 papers in Cancer Research and 120 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fátima Cardoso's work include Breast Cancer Treatment Studies (177 papers), HER2/EGFR in Cancer Research (122 papers) and Cancer Treatment and Pharmacology (95 papers). Fátima Cardoso is often cited by papers focused on Breast Cancer Treatment Studies (177 papers), HER2/EGFR in Cancer Research (122 papers) and Cancer Treatment and Pharmacology (95 papers). Fátima Cardoso collaborates with scholars based in Portugal, Belgium and United States. Fátima Cardoso's co-authors include Elżbieta Senkus, Martine Piccart, Frédérique Penault‐Llorca, Philip Poortmans, S. Kyriakides, Nadia Harbeck, Christos Sotiriou, Sophia Zackrisson, Emiel J. Rutgers and Shinji Ohno and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Fátima Cardoso

378 papers receiving 24.8k citations

Hit Papers

Breast cancer 2006 2026 2012 2019 2019 2022 2006 2019 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Breast cancer
    2019 2.0k citations Nadia Harbeck, Frédérique Penault‐Llorca et al. profile →
  2. Current and future burden of breast cancer: Global statistics for 2020 and 2040
    2022 1.7k citations Fátima Cardoso et al. The Breast profile →
  3. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
    2006 1.5k citations Denis Larsimont, Fátima Cardoso et al. profile →
  4. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2019 1.4k citations Fátima Cardoso, Frédérique Penault‐Llorca et al. Annals of Oncology profile →
  5. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2015 1.2k citations Frédérique Penault‐Llorca, Emiel J. Rutgers et al. Annals of Oncology profile →
  6. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
    2006 842 citations Jonas Bergh, Jan Bogaerts et al. profile →
  7. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    2011 807 citations Javier Cortés, Joyce O’Shaughnessy et al. profile →
  8. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
    2007 726 citations Jonas Bergh, Fátima Cardoso et al. Clinical Cancer Research profile →
  9. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
    2007 724 citations Evandro de Azambuja, Fátima Cardoso et al. profile →
  10. HER2-Low Breast Cancer: Pathological and Clinical Landscape
    2020 490 citations Fátima Cardoso, Frédérique Penault‐Llorca et al. profile →
  11. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
    2017 356 citations Nadia Harbeck, Fátima Cardoso et al. European Journal of Cancer profile →
  12. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
    2016 266 citations Fátima Cardoso, Maria João Cardoso et al. Annals of Oncology profile →
  13. Male breast cancer: a disease distinct from female breast cancer
    2018 230 citations Fátima Cardoso et al. Breast Cancer Research and Treatment profile →
  14. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
    2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers

Fátima Cardoso
Comparison fields: 5 of 181
  • Oncology 13.8k
  • Cancer Research 10.5k
  • Molecular Biology 7.4k
  • Pulmonary and Respiratory Medicine 4.9k
  • Genetics 3.2k
Replace Kathleen I. Pritchard with:
Kathleen I. Pritchard Canada
Antonio C. Wolff United States
John M.S. Bartlett United Kingdom
Jonas Bergh Sweden
Lisa A. Carey United States
Karen A. Gelmon Canada
Edith A. Perez United States
George W. Sledge United States
Carol DeSantis United States
Sibylle Loibl Germany
Kathleen I. Pritchard Canada View profile →
Citations per field, relative to Fátima Cardoso
Fátima Cardoso · 1×
Citations per year, relative to Fátima Cardoso
Fátima Cardoso · 1×

Countries citing papers authored by Fátima Cardoso

Since Specialization
Citations

This map shows the geographic impact of Fátima Cardoso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fátima Cardoso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fátima Cardoso more than expected).

Fields of papers citing papers by Fátima Cardoso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fátima Cardoso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fátima Cardoso. The network helps show where Fátima Cardoso may publish in the future.

Co-authorship network of co-authors of Fátima Cardoso

This figure shows the co-authorship network connecting the top 25 collaborators of Fátima Cardoso. A scholar is included among the top collaborators of Fátima Cardoso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fátima Cardoso. Fátima Cardoso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Best practices for communication of prognosis and end-of-life discussions with patients with advanced breast cancer: A report from the advanced breast cancer global alliance
2025 ·The Breast ·Lesley Fallowfield, Belinda E. Kiely, Luzia Travado, (unknown), (unknown), Fátima Cardoso
0
2
EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe
2024 ·European Journal of Cancer ·Michail Ignatiadis, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Fátima Cardoso, (unknown), David Cameron
2
3
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 breakdown →
2024 ·Annals of Oncology ·Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy, Javier Cortés, Rebecca Dent, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Y.H. Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fátima Cardoso, Ying Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid
47
4
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
2024 ·npj Breast Cancer ·Fátima Cardoso, Kim M. Hirshfield, Kimberly A. Kraynyak, Konstantinos Tryfonidis, Aditya Bardia
2
5
Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy
2024 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Francisco P. M. Oliveira, (unknown), Celeste Alves, María José Brito, Fátima Cardoso, Durval C. Costa
2
6
International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients
2023 ·Breast Cancer Research and Treatment ·Kelly M. de Ligt, Belle H. de Rooij, Elham Hedayati, Maria Margarete Karsten, (unknown), (unknown), Christobel Saunders, Luzia Travado, Fátima Cardoso, Elizabeth Lopez, (unknown), Yvonne Wengström, Angela Ives, Galina Velikova, (unknown), (unknown), Tanja Stamm, Linetta B. Koppert, Lonneke V. van de Poll‐Franse
10
7
Surgical choices and complications in elderly women: a single center retrospective analysis in frail vs. non frail breast cancer patients
2023 ·European Journal of Plastic Surgery ·(unknown), Márcio Debiasi, (unknown), (unknown), David Pinto, Pedro Gouveia, (unknown), (unknown), (unknown), Fátima Cardoso, Maria João Cardoso
1
8
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care
2023 ·European Journal of Cancer ·Fátima Cardoso, Amelia McCartney, Antonio Ponti, Lorenza Marotti, Conny Vrieling, Alexandru Eniu, Berta Sousa, Carla Ripamonti, Luzia Travado, (unknown), (unknown), Giuseppe Curigliano, Frédérique Penault‐Llorca, Frédéric Lecouvet, Isabel T. Rubio, Laura Biganzoli
7
9
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
2023 ·Annals of Oncology ·Peter Schmid, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Carsten Denkert, Y.H. Park, Rina Hui, (unknown), (unknown), Theodoros Foukakis, (unknown), (unknown), S-A. Im, Fátima Cardoso, Yu Ding, (unknown), Konstantinos Tryfonidis, Joyce O’Shaughnessy
20
10
LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
2023 ·Annals of Oncology ·Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Joyce O’Shaughnessy, Peter A. Fasching, Zhi-Min Shao, Delphine Loirat, Y.H. Park, (unknown), (unknown), Hiroyuki Yasojima, Yu Ding, (unknown), Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia
67
11
Unfolding the role of the PI3K/AKT/MTOR pathway in male breast cancer: A pragmatic appraisal
2023 ·The Breast ·Leonor Vasconcelos de Matos, Simona Ruxandra Volovăț, Márcio Debiasi, Fátima Cardoso
4
12
Patient-Reported Outcome Measures to Improve the Care Continuum for Patients With Metastatic Breast Cancer: Opportunities and Implications for Nursing Practice
2023 ·Seminars in Oncology Nursing ·Kelly M. de Ligt, Belle H. de Rooij, Linetta B. Koppert, Lonneke V. van de Poll‐Franse, Galina Velikova, Fátima Cardoso
2
13
Associations between Physical Exercise, Quality of Life, Psychological Symptoms and Treatment Side Effects in Early Breast Cancer
2022 ·The Breast Journal ·Leena Vehmanen, Johanna Mattson, Evangelos C. Karademas, Albino J. Oliveira‐Maia, Berta Sousa, Ruth Pat‐Horenczyk, Ketti Mazzocco, Panagiotis G. Simos, Fátima Cardoso, (unknown), Chiara Marzorati, Eleni Kolokotroni, Georgios Stamatakos, Diana Frasquilho, Paula Poikonen‐Saksela
11
14
Protocol for the Implementation and Assessment of “MoodUP”: A Stepped Care Model Assisted by a Digital Platform to Accelerate Access to Mental Health Care for Cancer Patients Amid the COVID-19 Pandemic
2021 ·International Journal of Environmental Research and Public Health ·Diana Frasquilho, Ricardo Matias, (unknown), Berta Sousa, (unknown), (unknown), Fátima Cardoso, Albino J. Oliveira‐Maia
5
15
Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer
2021 ·Breast Cancer Research and Treatment ·Josephine Lopes Cardozo, Marjanka K. Schmidt, Laura van ‘t Veer, Fátima Cardoso, Coralie Poncet, Emiel J. Rutgers, Caroline A. Drukker
4
16
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)
2014 ·The Breast ·P. Fumoleau, Kevin M. Koch, Étienne Brain, François Lokiec, Keyvan Rezaï, Ahmad Awada, Larry Hayward, Gustavo Werutsky, Jan Bogaerts, Sandrine Marréaud, Fátima Cardoso
10
17
Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel
2008 ·Clinical Cancer Research ·Carlos M. Galmarini, Isabelle Treilleux, Fátima Cardoso, Chantal Bernard-Marty, Virginie Durbecq, David Gancberg, Marie-Christine Bissery, Marianne Paesmans, Denis Larsimont, Martine Piccart, Angelo Di Leo, Charles Dumontet
55
18
[The new generation of breast cancer clinical trials: the right drug for the right target].
2008 ·PubMed ·Evandro de Azambuja, Fátima Cardoso, (unknown), Carolyn Straehle, Stella Dolci, K. Vantongelen, Martine Piccart
11
19
[News in the medical treatment of breast cancer].
2003 ·PubMed ·Martine Piccart, (unknown), Fátima Cardoso
4
20
HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
2002 ·PubMed ·Denis Larsimont, Angelo Di Leo, Ghizlane Rouas, Marianne Paesmans, (unknown), Chantal Bernard, Fátima Cardoso, Alain Verhest, Martine Piccart, David Gancberg
11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathleen I. Pritchard Breakdown of academic impact, for papers by Antonio C. Wolff Breakdown of academic impact, for papers by John M.S. Bartlett Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Lisa A. Carey Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Edith A. Perez Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Carol DeSantis Breakdown of academic impact, for papers by Sibylle Loibl
Rankless by CCL
2026